CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133

Phase 1RBD3133Positive
AI Analysis

Summary

Ribo announced successful submission of a Phase 1 Clinical Trial Application to the EU for RBD3133, an INHBE-targeting siRNA therapeutic.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Clinical Trial Application submitted to EU

Importance:5/10
Sentiment:
0.60
siRNAINHBE-targetingEuropean Clinical TrialCTA submission
Related Companies
$CPHI

Read the original article

Published by PR Newswire Pharma on October 8, 2026 2:57 AM

Read Original